Anticoagulation and ACS Practice Test

The main idea is that starting a high‑intensity statin right after an acute coronary syndrome reduces the risk of future events by rapidly lowering LDL and stabilizing plaque, while also providing anti‑inflammatory benefits. Guideline guidance supports initiating high‑intensity statin therapy as soon as possible, ideally within the first 24 hours, for all ACS patients unless there’s a contraindication. This approach should be continued long‑term, with dosing such as atorvastatin 40–80 mg daily or rosuvastatin 20–40 mg daily, depending on the patient’s factors and tolerability.

This is favored over moderate‑intensity therapy within the first 24 hours because the evidence supports greater risk reduction with higher LDL lowering early in the course of ACS. It’s also not appropriate to delay statin therapy to avoid potential side effects, and it isn’t limited to one specific drug—any high‑intensity statin that achieves substantial LDL lowering is appropriate.